Headlines about Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) have been trending positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corbus Pharmaceuticals Holdings earned a daily sentiment score of 0.36 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- BidaskClub Upgrades Corbus Pharmaceuticals Holdings, Inc. (CRBP) to “Hold” (americanbankingnews.com)
- Commit To Buy Corbus Pharmaceuticals Holdings At $5, Earn 17.2 … – TheStreet.com (thestreet.com)
- Share Activity Lifted for Corbus Pharmaceuticals Holdings Inc (CRBP) in Session – Evergreen Caller (evergreencaller.com)
- ResMed Inc. (RMD) registers a price change of -0.10% while Corbus … – Stocks Gallery (stocksgallery.com)
Corbus Pharmaceuticals Holdings (CRBP) opened at 6.40 on Monday. The firm’s market capitalization is $321.40 million. Corbus Pharmaceuticals Holdings has a 52-week low of $2.68 and a 52-week high of $10.78. The stock’s 50 day moving average price is $6.30 and its 200 day moving average price is $7.48.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The company had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 117.78% and a negative net margin of 874.41%. On average, analysts predict that Corbus Pharmaceuticals Holdings will post ($0.77) EPS for the current fiscal year.
Several research analysts have recently weighed in on CRBP shares. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Saturday, May 6th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, April 5th. BidaskClub raised Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, JMP Securities reaffirmed an “outperform” rating and set a $27.00 price objective (up from $20.00) on shares of Corbus Pharmaceuticals Holdings in a research report on Monday, April 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $20.50.
TRADEMARK VIOLATION WARNING: “Corbus Pharmaceuticals Holdings (CRBP) Given Daily Media Impact Rating of 0.36” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.wkrb13.com/markets/2285303/corbus-pharmaceuticals-holdings-crbp-given-daily-media-impact-rating-of-0-36.html.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285303/corbus-pharmaceuticals-holdings-crbp-given-daily-media-impact-rating-of-0-36.html
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.